Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man

A. Peñalva, L. Villanueva, F. Casanueva, F. Cavagnini, A. Gomez-Pan, E. E. Müller

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Studies were performed in healthy subjects to ascertain the neurotransmitter systems involved in the growth hormone (GH)-releasing effect of the potent enkephalin analog FK 33-824. Concomitant evaluation of prolactin (PRL) secretion was also performed in the same subjects. FK 33-824 at a dose of 0.5 mg IV elicited a clear-cut rise in plasma GH and PRL concentrations with peak levels at 45 min. Blockade of muscarinic cholinergic receptors by atropine (0.5 mg SC) or histaminergic H1 receptors by diphenhydramine (50 mg IV bolus plus 50 mg infusion) completely suppressed the GH release induced by FK 33-824, without significantly altering the PRL rise induced by the peptide. Pretreatment with the alpha-adrenergic antagonist phentolamine (0.5 mg IV/min for 120 min) or the dopamine receptor blocker metoclopramide (10 mg IV) did not alter the GH-releasing effect of FK 33-824. Phentolamine failed to alter the PRL rise induced by FK 33-824, while combined FK 33-824-metoclopramide administration induced a greater PRL increase than FK 33-824 alone. These results indicate that cholinergic and histaminergic H1 receptors play an important role in the GH-release induced by FK 33-824 in man, whereas this action seems to occur independently of catecholaminergic mediation. The same receptors are not involved in the PRL-releasing effect of the peptide.

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalPsychopharmacology
Volume80
Issue number2
DOIs
Publication statusPublished - May 1983

Fingerprint

D-Ala(2),MePhe(4),Met(0)-ol-enkephalin
Enkephalins
Cholinergic Agents
Growth Hormone
Prolactin
Histamine H1 Receptors
Metoclopramide
Phentolamine
Prolactin-Releasing Hormone
Adrenergic alpha-Antagonists
Diphenhydramine
Dopamine Antagonists
Dopamine Receptors
Cholinergic Receptors
Muscarinic Receptors
Atropine
Neurotransmitter Agents
Healthy Volunteers

Keywords

  • Catecholaminergic system
  • Cholinergic system
  • FK 33-824
  • Growth hormone
  • Histaminergic system
  • Opoid peptides
  • Prolactin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man. / Peñalva, A.; Villanueva, L.; Casanueva, F.; Cavagnini, F.; Gomez-Pan, A.; Müller, E. E.

In: Psychopharmacology, Vol. 80, No. 2, 05.1983, p. 120-124.

Research output: Contribution to journalArticle

Peñalva, A. ; Villanueva, L. ; Casanueva, F. ; Cavagnini, F. ; Gomez-Pan, A. ; Müller, E. E. / Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man. In: Psychopharmacology. 1983 ; Vol. 80, No. 2. pp. 120-124.
@article{e73eba5662a7402aab2a04e5d9fb684c,
title = "Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man",
abstract = "Studies were performed in healthy subjects to ascertain the neurotransmitter systems involved in the growth hormone (GH)-releasing effect of the potent enkephalin analog FK 33-824. Concomitant evaluation of prolactin (PRL) secretion was also performed in the same subjects. FK 33-824 at a dose of 0.5 mg IV elicited a clear-cut rise in plasma GH and PRL concentrations with peak levels at 45 min. Blockade of muscarinic cholinergic receptors by atropine (0.5 mg SC) or histaminergic H1 receptors by diphenhydramine (50 mg IV bolus plus 50 mg infusion) completely suppressed the GH release induced by FK 33-824, without significantly altering the PRL rise induced by the peptide. Pretreatment with the alpha-adrenergic antagonist phentolamine (0.5 mg IV/min for 120 min) or the dopamine receptor blocker metoclopramide (10 mg IV) did not alter the GH-releasing effect of FK 33-824. Phentolamine failed to alter the PRL rise induced by FK 33-824, while combined FK 33-824-metoclopramide administration induced a greater PRL increase than FK 33-824 alone. These results indicate that cholinergic and histaminergic H1 receptors play an important role in the GH-release induced by FK 33-824 in man, whereas this action seems to occur independently of catecholaminergic mediation. The same receptors are not involved in the PRL-releasing effect of the peptide.",
keywords = "Catecholaminergic system, Cholinergic system, FK 33-824, Growth hormone, Histaminergic system, Opoid peptides, Prolactin",
author = "A. Pe{\~n}alva and L. Villanueva and F. Casanueva and F. Cavagnini and A. Gomez-Pan and M{\"u}ller, {E. E.}",
year = "1983",
month = "5",
doi = "10.1007/BF00427953",
language = "English",
volume = "80",
pages = "120--124",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man

AU - Peñalva, A.

AU - Villanueva, L.

AU - Casanueva, F.

AU - Cavagnini, F.

AU - Gomez-Pan, A.

AU - Müller, E. E.

PY - 1983/5

Y1 - 1983/5

N2 - Studies were performed in healthy subjects to ascertain the neurotransmitter systems involved in the growth hormone (GH)-releasing effect of the potent enkephalin analog FK 33-824. Concomitant evaluation of prolactin (PRL) secretion was also performed in the same subjects. FK 33-824 at a dose of 0.5 mg IV elicited a clear-cut rise in plasma GH and PRL concentrations with peak levels at 45 min. Blockade of muscarinic cholinergic receptors by atropine (0.5 mg SC) or histaminergic H1 receptors by diphenhydramine (50 mg IV bolus plus 50 mg infusion) completely suppressed the GH release induced by FK 33-824, without significantly altering the PRL rise induced by the peptide. Pretreatment with the alpha-adrenergic antagonist phentolamine (0.5 mg IV/min for 120 min) or the dopamine receptor blocker metoclopramide (10 mg IV) did not alter the GH-releasing effect of FK 33-824. Phentolamine failed to alter the PRL rise induced by FK 33-824, while combined FK 33-824-metoclopramide administration induced a greater PRL increase than FK 33-824 alone. These results indicate that cholinergic and histaminergic H1 receptors play an important role in the GH-release induced by FK 33-824 in man, whereas this action seems to occur independently of catecholaminergic mediation. The same receptors are not involved in the PRL-releasing effect of the peptide.

AB - Studies were performed in healthy subjects to ascertain the neurotransmitter systems involved in the growth hormone (GH)-releasing effect of the potent enkephalin analog FK 33-824. Concomitant evaluation of prolactin (PRL) secretion was also performed in the same subjects. FK 33-824 at a dose of 0.5 mg IV elicited a clear-cut rise in plasma GH and PRL concentrations with peak levels at 45 min. Blockade of muscarinic cholinergic receptors by atropine (0.5 mg SC) or histaminergic H1 receptors by diphenhydramine (50 mg IV bolus plus 50 mg infusion) completely suppressed the GH release induced by FK 33-824, without significantly altering the PRL rise induced by the peptide. Pretreatment with the alpha-adrenergic antagonist phentolamine (0.5 mg IV/min for 120 min) or the dopamine receptor blocker metoclopramide (10 mg IV) did not alter the GH-releasing effect of FK 33-824. Phentolamine failed to alter the PRL rise induced by FK 33-824, while combined FK 33-824-metoclopramide administration induced a greater PRL increase than FK 33-824 alone. These results indicate that cholinergic and histaminergic H1 receptors play an important role in the GH-release induced by FK 33-824 in man, whereas this action seems to occur independently of catecholaminergic mediation. The same receptors are not involved in the PRL-releasing effect of the peptide.

KW - Catecholaminergic system

KW - Cholinergic system

KW - FK 33-824

KW - Growth hormone

KW - Histaminergic system

KW - Opoid peptides

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0020586493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020586493&partnerID=8YFLogxK

U2 - 10.1007/BF00427953

DO - 10.1007/BF00427953

M3 - Article

VL - 80

SP - 120

EP - 124

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -